Detail akcie Vor Biopharma Rg online

Business Summary: Vor Biopharma Inc. is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a dual-target fusion protein, through Phase III clinical development and commercialization to address serious autoantibody-driven conditions worldwide. Telitacicept is an investigational recombinant fusion protein designed to treat autoimmune diseases by selectively inhibiting BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase III clinical trial in gMG is underway across the United States, Europe, and South America to support potential approval in the United States and Europe.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Vor Biopharma Inc revenues was not reported. Net loss increased from $86.2M to $2.42B. Higher net loss reflects Research and development - Balancing val increase from $64.1M to $300.2M (expense), General and administrative - Balancing increase of 34% to $23.7M (expense), Stock-based Compensation in SGA increase from $4.3M to $9.7M (expense).